Early extracranial dissemination with prolonged survival in IDH-wildtype glioblastoma: case study and comprehensive literature review Authors: Colin Burns, Cheng Chia Wu, Kei Suzuki, Grace Lee, Daniel Kim Published: 2026 ABSTRACT AbstractBackgroundExtracranial metastasis of glioblastoma (GBM) is rare (0.4–2%) and associated with poor prognosis. For this report, “early extracranial dissemination” is defined as radiographically and histologically confirmed metastatic disease identified at or within one month of the index GBM diagnosis, distinguishing it from metastasis arising later in the disease course.Case presentationA 65-year-old woman with IDH-wildtype, MGMT-methylated GBM presented with seizures, right hemiplegia, and expressive aphasia. She underwent near-total resection followed by chemoradiotherapy with temozolomide. A suspicious right lower lobe pulmonary lesion was identified on initial staging, and biopsy-confirmed GBM involving mediastinal lymph nodes was established within one month of diagnosis. Despite pulmonary and mediastinal involvement, intracranial hemorrhage, seizures, and venous thromboembolism, she survived 25 months from diagnosis and 24 months following confirmation of metastatic disease.DiscussionThis case is notable for exceptionally early extracranial dissemination, pulmonary and mediastinal involvement, and prolonged post-metastatic survival. MGMT methylation and sustained temozolomide therapy may have contributed to disease control, although these observations remain hypothesis-generating.ConclusionEarly extracranial dissemination may be underrecognized and warrants further investigation through risk-stratified approaches to extracranial surveillance.Keywords: Glioblastoma, extracranial metastases, pulmonary metastases, temozolomide, radiation therapy Introduction: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults with a median overall survival ranging from 1.5 to 2 years. However, metastatic GBM is a rare progression, with a reported incidence rate of 0.4–2% of all GBM cases [1–5]. The absence of lymphatic vessels in the central nervous system (CNS), the lack of communication between intracranial and extracranial perivascular spaces, short survival times, and undiagnosed metastatic disease are possible explanations regarding the rarity of GBM metastases [6–8]. More recently, the identification of meningeal lymphatic pathways together with improvements in systemic imaging has renewed interest in the mechanisms responsible for extracranial dissemination. Emerging evidence has demonstrated that circulating tumor cells are detectable in the peripheral blood of approximately 20% of GBM patients, and that the circulating tumors cell release is associated with EGFR gene amplification, suggesting that hematogenous dissemination may be an intrinsic factor of GBM biology rather than an exceptional event [9–11]. GBM metastasis most commonly occurs in bone, lymph nodes (thoracic and cervical), lung, leptomeninges, and soft tissues [12]. The mechanism of GBM metastasis is not well known, but has been postulated to occur as a result of hematogenous or lymphatic spread [13]. Recent molecular studies have further demonstrated that extracranial metastases originate from the primary tumor rather than later recurrences, and that tumor plasticity, including changes in epigenetic methylation classes and transcriptional subtypes, occurs during progression to metastasis [14]. Median time from diagnosis of primary GBM to metastasis is 8.5–11 months, and median time from detection of metastasis to death is 1.5 months [1,15]. The clinical presentation of patients with metastatic GBM is typically dependent on the site of metastases. A standard treatment plan does not currently exist in the setting of extracranial metastasis. Surgery, radiation, and systemic chemotherapy or bevacizumab are all considered potential options [16]. As survival among patients with GBM continues to improve modestly through multimodal treatment, extracranial metastases may become increasingly recognized. However, important knowledge gaps remain regarding the mechanisms of dissemination, factors associated with prolonged survival, and optimal management once metastatic disease develops. Here, we report a case of a 65-year-old woman who developed GBM metastatic to various sites, including the mediastinal lymph nodes and the right lower lobe of her lungs. Lun et al. reported that lung metastasis in GBM is associated with a 2.7-month decrease in the median interval from the detection of extracranial metastasis to death compared to other metastatic sites [1]. Against this clinical context, the present case is notable for biopsy-confirmed extracranial dissemination within one month of the initial GBM diagnosis, concurrent pulmonary and mediastinal involvement, and prolonged survival of 24 months following the diagnosis of metastatic disease. By placing this case within the context of a comprehensive literature review, we aim to further characterize this uncommon pattern of GBM dissemination and identify factors that may contribute to metastatic behavior and clinical outcomes. In particular, this case highlights the unusual coexistence of two features that are individually uncommon in metastatic GBM, very early extracranial dissemination and prolonged post-metastatic survival, and raises the possibility that tumor-intrinsic molecular characteristics, local treatment of pulmonary metastases, and host and clinical factors may collectively influence the trajectory of extracranial disease. Case presentation Initial presentation and diagnosis A 65-year-old woman developed new-onset seizures while visiting family in California. She presented with right hemiplegia and expressive aphasia. Imaging revealed a 4 cm left prefrontal tumor (Figure 1). Initial staging chest computed tomography (CT), performed during the diagnostic workup in late June 2021, demonstrated a 2.3 cm right lower lobe lesion with central necrosis causing near-complete bronchial obstruction and associated air trapping, raising concern for extracranial metastatic disease. Brain MRI performed the same day demonstrated a 4.1 × 1.9 × 2.1 cm heterogeneously enhancing mass involving the left precentral gyrus with surrounding vasogenic edema and evidence of cortical invasion (Figure 2). Non-contrast head CT at initial presentation. A large left prefrontal intraparenchymal mass is identified with surrounding vasogenic edema and rightward midline shift. The patient presented with new-onset seizures, right hemiplegia, and expressive aphasia. Preoperative contrast-enhanced brain MRI (T1-weighted post-gadolinium). A 4.1 × 1.9 × 2.1 cm heterogeneously enhancing mass involving the left precentral gyrus is demonstrated with surrounding vasogenic edema and evidence of cortical invasion, consistent with high grade glioma. Three days later, a near-total neurosurgical resection was performed. Pathology confirmed a World Health Organization (WHO) grade 4, IDH-wildtype GBM with MGMT promoter methylation. Immunohistochemistry demonstrated IDH1 R132H negativity, with IDH-wildtype status confirmed by IDH-1 and IDH-2 sequencing. p53 immunohistochemistry demonstrated nuclear positivity in approximately 60% of tumor cells, a pattern suggestive of, but not diagnostic of, an underlying TP53 mutation; molecular confirmation of TP53 mutational status was not performed. The Ki-67 labeling index was estimated at 40%, indicating a high proliferative rate.17 ATRX was retained. A detailed summary of the immunohistochemical and molecular features of the primary tumor is provided in Table 1. Table 1.Summary of immunohistochemistry and molecular features of our patient’s primary tumor.IDH-1/-2Wild-typeIDH1 R132HNegativeMGMTMethylatedTP53Positive (60% of tumor cells)Ki67Labeling index estimated at 40%ATRXRetained Expression Summary of immunohistochemistry and molecular features of our patient’s primary tumor. Confirmation of extracranial metastasis Endobronchial ultrasound (EBUS)-guided biopsy of mediastinal lymph nodes was performed in early July 2021, approximately one week after craniotomy. Histopathologic examination of the mediastinal lymph node biopsy demonstrated tumor cells with morphologic features consistent with the primary intracranial neoplasm. Immunohistochemistry confirmed glial fibrillary acidic protein (GFAP) positivity, establishing glial lineage, while TTF-1 negativity effectively excluded a primary pulmonary adenocarcinoma. The combination of GFAP positivity and TTF-1 negativity, together with morphologic concordance with the primary intracranial tumor, established the diagnosis of metastatic GBM. Molecular profiling of the metastatic mediastinal lymph node using the UCSF500 next-generation sequencing (NGS) assay demonstrated a diploid tumor without significant copy-number alterations and identified a SOX10 mutation. While SOX10 expression is also characteristic of melanoma and peripheral nerve sheath tumors, the overall immunohistochemical profile (GFAP-positive, TTF-1-negative) and morphologic features were consistent with metastatic GBM rather than a primary melanocytic or pulmonary neoplasm. Although representative histopathologic images from the outside institution were unavailable despite multiple attempts to obtain them, the diagnosis was established based on the original pathology interpretation and molecular findings. Early complications Three weeks later, the patient returned to Virginia for further treatment with persistent right hemiparesis and expressive aphasia greater than receptive aphasia. Before initiating adjuvant therapy, she experienced a second seizure requiring hospitalization. Head CT demonstrated a left frontal intraparenchymal hemorrhage. The intracranial hemorrhage likely reflected a combination of tumor bed hemorrhage and the prophylactic anticoagulation she was receiving (enoxaparin 40 mg daily) for a concurrent pulmonary embolism (PE), for which an inferior vena cava (IVC) filter was placed. These early complications are well-recognized features of GBM that can significantly complicate treatment delivery and reflect the prothrombotic state associated with high-grade gliomas. Follow-up imaging one week later confirmed stable intracranial hemorrhage with persistent mass effect. CT of the chest, abdomen, and pelvis demonstrated the previously identified 2.3 cm right lower lobe lesion with stable near-complete bronchial obstruction (Figure 3). Contrast-enhanced CT of the chest demonstrating extracranial metastatic disease. A 2.3 cm well-circumscribed lesion with central necrosis is seen in the paramediastinal right lower lobe, abutting the bronchus intermedius with ear-complete luminal effacement resulting in air trapping and hyperinflation of the right middle and lower lobes. Biopsy confirmed metastatic GBM. Radiation therapy and chemoradiotherapy Because of progressive bronchial compression by the metastatic pulmonary lesion, urgent palliative radiation therapy was initiated in early August 2021. The patient received 30 Gy in 10 fractions to the right lower lobe lesion over approximately two weeks. Following completion of thoracic radiation, she underwent standard-of-care concurrent chemoradiotherapy for her primary intracranial GBM, receiving temozolomide with external beam radiation therapy to a total dose of 40 Gy in 15 fractions to the left frontal surgical cavity between late August and early October 2021. Post-treatment course and disease monitoring Two weeks following completion of chemoradiotherapy, the patient was hospitalized for weakness, somnolence, and worsening aphasia. MRI of the brain demonstrated persistent postoperative edema and the known intraparenchymal hematoma without evidence of an acute new intracranial event. She was treated with dexamethasone, resulting in clinical improvement. Surveillance imaging over the ensuing months demonstrated fluctuating intracranial findings with persistent concern for residual viable tumor. In December 2021, brain MRI showed a smaller postoperative cavity with persistent peripheral enhancement and elevated perfusion, concerning for viable tumor, along with new infiltrative signal abnormality extending into the brainstem and upper cervical spinal cord. Concurrent chest CT showed slight interval enlargement of the right perihilar lesion. In February 2022, the patient was hospitalized for breakthrough seizures. Brain MRI demonstrated a 7.1 cm enhancing left frontoparietal lesion with surrounding vasogenic edema, concerning for disease progression. Follow-up thoracic imaging in March 2022 demonstrated a slight decrease in the size of the treated pulmonary lesion, suggesting a partial response to prior radiation therapy. Shortly thereafter, the patient developed extensive bilateral lower extremity edema. Venous Doppler ultrasonography demonstrated extensive bilateral femoral deep venous thromboses. Because of her recent intracranial hemorrhage, therapeutic anticoagulation was deferred, and she was managed conservatively with the previously placed IVC filter. Brain MRI in April 2022 showed findings concerning for possible tumor progression, with enhancing tissue demonstrating elevated cerebral blood volume. Despite these findings and the accumulated complications, the patient's neurological function improved sufficiently to permit re-initiation of temozolomide in late April 2022. Follow-up brain MRI in June 2022 demonstrated stable postoperative changes with persistent enhancing tissue and stable peritumoral edema. Disease progression and end of life Over the following months, she continued temozolomide therapy. Treatment was temporarily held in late June 2022 because of fatigue, thrombocytopenia, and COVID-19 infection. Her subsequent clinical course was further complicated by vertebral compression fractures. MRI performed in January 2023 demonstrated intracranial progression. Temozolomide therapy was continued until a repeat MRI in June 2023 confirmed unequivocal disease progression, at which point she transitioned to hospice-directed care. The patient ultimately died in August 2023, approximately 25 months after her initial GBM diagnosis and 24 months after biopsy-confirmed extracranial metastatic disease. A chronological timeline of the key clinical events is presented in Figure 4. Clinical timeline illustrating the patient's disease course from initial diagnosis (June 2021) through death (August 2023). Figure was created using OpenAI ChatGPT (GPT-5.5) with image generation based on the following prompt: “Please create a timeline figure showing the following milestones: Initial diagnosis/surgery (June 2021) → EBUS biopsy confirming metastasis (July 2021) → Intracranial hemorrhage/PE/IVC filter (July 2021) → Lung RT 30 Gy/10 fractions (August 2021) → Brain chemoradiotherapy 40 Gy/15 fractions + TMZ (August–October 2021) → Hospitalization for edema/symptoms (October 2021) → Surveillance imaging showing mixed response (December 2021) → Breakthrough seizures (February 2022) → Partial pulmonary response/bilateral DVT (March 2022) → TMZ restart (April 2022) → TMZ held for COVID-19/thrombocytopenia (June 2022) → Brain progression (January 2023) → Further progression/hospice (June 2023) → Death (August 2023).” The authors reviewed and edited the final figure for accuracy. Literature review methodology PubMed/MEDLINE and Embase were searched from inception through March 2026 using combinations of the terms “glioblastoma,” “glioblastoma multiforme,” “extracranial metastasis,” “extraneural metastasis,” “distant metastasis,” and site-specific terms including “lung,” “pulmonary,” “lymph node,” “bone,” and “soft tissue.” English-language case reports and case series reporting histologically confirmed extracranial GBM metastasis were included. Reference lists of retrieved articles and prior reviews were manually screened for additional cases. Cases were included if they reported the time from primary diagnosis to metastasis and/or post-metastatic survival; reports lacking histologic confirmation of extracranial disease were excluded. Data extracted for Table 2 comprised patient age and sex, metastatic site(s), interval from diagnosis to metastasis, and survival after metastasis. Table 2.Case reports of metastatic GBM.PublicationAge/ SexPrimary Tumor LocationEORPre-Metastasis TreatmentMetastatic Site(s)Interval Dx → Met (mo)Sarcomatous ComponentMetastasis TreatmentOutcomeInterval Met → Death (mo)Interval Dx → Death (mo)Present Case65/FL frontalNTRN/ALN, lung1NoXRT, TMZPD2425Potter et al., 198341/ML frontalSTRWBRTSubmandibular11NRXRT, lomustineSD at 9 moNRNRWallace et al., 199641/MR frontalGTRXRT, carmustineLNNRNRXRT, chemoAspirationNR8Beauchesne et al., 200054/MR temporalSTRXRT, etoposideHeart, lung, bone7NRNRNR29Houston et al., 2000 (Case 1)19/ML parietalSTRXRT, ¹²5I brachytherapyBone16NRRT, cisplatin, etoposide, MTX/doxorubicin/vincristine/paclitaxelRecurrence117Houston et al., 2000 (Case 2)32/ML temporalSTRXRT, carmustine, ¹²5I brachytherapyScalp6YesExcisionRecurrence613Houston et al., 2000 (Case 3)36/FFrontalBxXRT, ¹²5I brachytherapyNeck17NRProcarbazinePD926Hübner et al., 200147/MR cerebellumNRXRT, chemoNeck, LN10NRRTPD717Allan, 200460/MNRSTRXRTScalp12NRSteroidsNR214Ogungbo et al., 200549/FR occipitalResectionXRT, lomustine, procarbazineLung, parotid gland7NRNRNRNR16Taha et al., 200533/ML frontalSTRXRTParotid gland6NRXRT, PCVPD3.5NRTempleton et al., 2008 (Case 1) 58/ML frontalGTRXRT, TMZEpidural spine, lung, bone, retroperitoneum5YesResection, XRT, TMZSoft tissue/spine metastases, PE611Templeton et al., 2008 (Case 2) 47/FR frontalSTRTMZPleura24NRNRRespiratory insufficiency2424Zhen et al., 2010 25/MR frontoparietalGTRRe-resection, XRTBone, LN2NoChemoNRNRNRArmstrong et al., 2011 30/FL frontalSTRXRT, TMZ, sorafenib, erlotinibSoft tissue (scalp)NRNoIrinotecan, bevacizumabSD 11 mo, then bone metastasesNRNRKalokhe et al., 2012 (Case 1) 72/MR temporal/occipitalGTRXRT, TMZ, BEV, carmustineLung, bone10NRNRNR919Kalokhe et al., 2012 (Case 2) 31/FL cerebellumGTRErlotinib, BEVBone4NRRT, TMZ, BEVPD59Seo et al., 2012 46/ML frontoparietalResectionGKRS, PCV, TMZCervical LN60NRResection, adjuvant therapyPD666Blume et al., 2013 40/MR parasagittalSTRXRT, TMZLung, LN, bone, muscle, epidural36NRSTR, XRT, TMZNRNRNRDawar et al., 2013 57/FR temporalGTRXRT, TMZPre-auricular region51NRMAID, gemcitabine/docetaxel, SRSPD6.557.5Lettau et al., 2013 80/NRL temporalGTRXRT, TMZDura7NRResectionNRNRNRRomero-Rojas et al., 2013 26/MFrontalNRXRT, TMZParotid gland, LN, boneNRNRXRT, TMZNRNRNRUndabeitia et al., 2015 20/FR temporalGTRXRT, chemoLung5NRNRNR38Anghileri et al., 2016 (Case 1) 30/ML central sulcusNRXRT, RT, re-resection, BEVNeck82NoNRPD1.583.5Anghileri et al., 2015 (Case 2) 43/ML frontalGTRXRT, TMZ, BEV, re-resectionSubcutaneous23.5NRNRPD1.525Lewis et al., 2017 47/FL cerebellumGTRXRT, TMZSoft tissue, LMNRNRCSI, TMZ, thymalfasinSD (LMD); excision of subcutaneous massNRNRSimonetti et al., 2017 38/ML parietalGTRXRT, TMZ, re-resection, BEVLung, LN, bone48NREtoposide, hydroxyureaLiver metastases, hemorrhage, pleural effusionNRNRHori et al., 2018 75/FL frontotemporal, L BG, R frontalSTR–LN, pleura2.8NRNRRespiratory failure0.33.4Janik et al., 2019 51/MR temporalGTRXRT, TMZLung3NRNRNR3.522.5Tamai et al., 2019 49/MR temporalGTRXRT, TMZVentricle, dura, LM, lungNRNRResection, XRT, TMZ, BEVRespiratory failureNR12Hsu et al., 2020 53/FR temporo-parieto-occipitalNTRPBRT, re-resection, carmustine wafers, TMZ, BEVBone15YesResectionNRNR20Liu et al., 2020 46/ML temporalGTRXRT, TMZScalp6NRXRT, irinotecan, TMZLung metastases at 9 mo1420Rossi et al., 2020 29/FR frontalSTRMultiple resections, XRT, TMZLN, bone39NRXRT, procarbazine, lomustinePD, sepsis1248Umphlett et al., 2020 74/FL occipitalResectionXRT, TMZ, SRSLung, heart, breast, liver, thyroid, bowel, bone, LN1NoNRNRNR12Sickler et al., 2021 57/MR temporalNTRXRT, TMZBone12NoXRT, TMZNRNRNRZhang et al., 2021 47/ML temporalGTRXRT, TMZBone, spine31NRXRT, TMZPD1243Al-Sardi et al., 2022 43/FR parasagittalGTRXRT, TMZ, atorvastatin, BEV, multiple resections, irinotecan, re-RTLung, LN59NoCarboplatin, etoposideNRNRNRKumaria et al., 2022 65/ML temporalSTRXRT, TMZLung17NRNRRespiratory failureNRNRNakib et al., 2022 53/MR PLIC/thalamusSTRXRT, TMZ, BEV, lomustine, irinotecanSkin6NoBEVAsystoleNRNRYuen et al., 2024 63/FL frontalNTRXRT, TMZ, BEV, lomustineLung8.5YesLenvatinibPD1.510Taule et al., 2024 55/ML temporalNTRXRT, TMZLN, bone, lung, spine, soft tissue, mesentery10NRXRT, lomustine, BEV, vincristinePD211XRT: External Beam Radiotherapy; RT: Radiotherapy; WBRT: Whole Brain Radiotherapy; SRS: Stereotactic Radiosurgery; GKRS: Gamma Knife Radiosurgery; PBRT: Proton Beam Radiotherapy; CSI: Craniospinal Irradiation; TMZ: Temozolomide; CCNU: Lomustine; BCNU: Carmustine; BEV: Bevacizumab; PCV: Procarbazine, CCNU, and Vincristine; VP-16: Etoposide; MTX: Methotrexate; PD: Progressive Disease; SD: Stable Disease; GTR: Gross Total Resection; STR: Subtotal Resection; NTR: Near Total Resection; Bx: Biopsy; NR: Not Reported; N/A: Not Applicable; Dx: Diagnosis; LN: Lymph Node(s); LM/LMD: Leptomeningeal Disease. Case reports of metastatic GBM. XRT: External Beam Radiotherapy; RT: Radiotherapy; WBRT: Whole Brain Radiotherapy; SRS: Stereotactic Radiosurgery; GKRS: Gamma Knife Radiosurgery; PBRT: Proton Beam Radiotherapy; CSI: Craniospinal Irradiation; TMZ: Temozolomide; CCNU: Lomustine; BCNU: Carmustine; BEV: Bevacizumab; PCV: Procarbazine, CCNU, and Vincristine; VP-16: Etoposide; MTX: Methotrexate; PD: Progressive Disease; SD: Stable Disease; GTR: Gross Total Resection; STR: Subtotal Resection; NTR: Near Total Resection; Bx: Biopsy; NR: Not Reported; N/A: Not Applicable; Dx: Diagnosis; LN: Lymph Node(s); LM/LMD: Leptomeningeal Disease. Discussion: While extracranial metastasis of GBM remains rare, its recognition has increased over the past decade as improvements in patient survival, molecular diagnostics, and imaging have facilitated identification of systemic disease. The incidence rate of extracranial metastatic GBM may remain underestimated due to short survival durations, limited systemic imaging, and the brain’s unique anatomical and immunologic environment, including the absence of conventional lymphatic drainage pathways [6,7]. Consequently, extracranial metastasis may represent not only a rare biological event but also one that has historically been underrecognized. Our case adds to this evolving picture, demonstrating biopsy-confirmed pulmonary and mediastinal metastases within one month of diagnosis, one of the earliest reported presentations of extracranial metastatic GBM. Among reported cases in the literature, the most common sites of GBM metastases include the lungs, lymph nodes, bones, soft tissue, and liver. Lung involvement in particular is associated with a markedly poor prognosis and reduced overall survival. Lun et al. reported that lung metastasis in GBM shortens the median time from detection of metastases to death by approximately 2.7 months compared to all other metastatic sites [1]. Despite developing pulmonary metastases at an unusually early time point, our patient survived 24 months after biopsy-confirmed metastatic disease and 25 months following her initial diagnosis, substantially exceeding both the median survival reported by Lun et al. and the aggregate outcomes summarized in the published literature. Accordingly, the clinical significance of this case lies not only in the unusually early metastatic presentation, but also in the unexpectedly prolonged survival despite pulmonary involvement. A review of over 40 published metastatic GBM cases (Table 2) reveals a median interval of 7–10 months between initial GBM diagnosis and detection of metastasis [6,13,15,17–48]. Early metastatic spread within 1–3 months has been documented in four of the above-mentioned cases [13,36,37,42]. Only one other case demonstrated metastatic spread within one month, placing our case among the rarest early metastatic presentations [42]. Moreover, our patient experienced prolonged survival following metastasis (24 months), exceeding the median post-metastasis survival time of 5.5 months seen in the cases included in Table 2. Notably, Templeton et al, Liu et al, Rossi et al, and Zhang et al also reported relatively prolonged survival ranging from 12–24 months post-metastasis [25,40,41,44]. Collectively, these observations suggest that although uncommon, prolonged survival after extracranial dissemination is possible and may reflect biologic heterogeneity rather than a uniformly aggressive disease course. Survival following extracranial GBM dissemination is likely determined by multiple interacting factors, including intrinsic tumor biology (e.g., MGMT methylation status and proliferative index), the extent and success of localized treatment of the metastatic lesion, and individual patient characteristics such as performance status and treatment tolerance. The prolonged survival observed here should therefore be interpreted as multifactorial rather than attributable to any single variable. The biological drivers underlying extracranial dissemination remain poorly defined. Hematogenous spread following surgical disruption of the blood-brain barrier, circulating tumor cells, and glymphatic or recently characterized meningeal lymphatic pathways have all been proposed [10,49–53]. Emerging evidence suggests that extracranial dissemination may occur independently of surgical intervention and may be influenced by tumor-specific molecular characteristics and clonal evolution [10,14]. The molecular profile of the present case provides several points of integration with proposed metastatic mechanisms, though all such inferences from a single case are necessarily speculative. First, the p53 immunopositivity in 60% of tumor cells raises the possibility of an underlying TP53 alteration. This finding is of particular relevance to extracranial dissemination because Zhang et al. reported that TP53 mutations were significantly more frequent in GBM cases with extraneural metastasis (64.5%, 20/31) compared to unselected GBM from TCGA (22.6%, 56/248; P < 0.001) [50]. The p53 pathway is deregulated in approximately 84% of GBM patients, and gain-of-function TP53 mutations have been implicated in promoting GBM cell invasion, migration, proliferation, and evasion of apoptosis [54]. Loss of wild-type p53 function also disrupts pathways that inhibit metastasis, and transcriptionally defective TP53 mutants are known to gain additional functions that actively promote metastatic dissemination [55]. Thus, the TP53 alteration in this patient's tumor may represent a molecular feature that contributed to the propensity for early extracranial spread, consistent with the enrichment of TP53 mutations observed in the metastatic GBM literature. Second, the Ki-67 labeling index of 40% is substantially above the median of approximately 27.5% reported for IDH-wildtype glioblastomas and exceeds the ≥20% threshold that has been identified as an independent predictor of shorter progression-free survival in IDH-wildtype GBM [56–58]. Multiple studies have demonstrated that Ki-67 labeling index ≥20% is associated with significantly shorter overall survival and progression-free survival in IDH-wildtype GBM, with one study reporting median overall survival of 479 days (95% CI, 370–559) in patients with high Ki-67 indices compared to 1,243 days (95% CI, 666–NA) in those with lower indices [59]. The high proliferative rate in this case may have facilitated the rapid accumulation of genetic alterations necessary for metastatic competence, though this remains speculative. Third, the SOX10 mutation identified in the metastatic lung lesion is of particular interest. SOX10 has been identified as a master regulator of the RTK I epigenetic subtype of GBM, and its loss or disruption causes a subtype switch analogous to the proneural-mesenchymal transition, resulting in increased tumor invasion, immune cell infiltration, and significantly reduced survival in preclinical models [60]. Man et al. further demonstrated that low SOX10 expression is linked to neural stem cell-like GBM cell states and is a consequence of temozolomide treatment, with SOX10 suppression sufficient to induce tumor progression to an aggressive developmental-like phenotype [61]. In clinical cohorts, low SOX10 levels have been associated with poor overall survival in GBM, with SOX10 serving as an independent prognostic factor particularly in female patients [62]. In the present case, the presence of a SOX10 mutation raises the question of whether disruption of SOX10 function may have contributed to the metastatic phenotype through promotion of a mesenchymal or stem cell-like transition. It must be emphasized that p53 immunopositivity and the identified SOX10 variant indicate the presence of molecular alterations, but do not, in the absence of functional assays, establish that these alterations drove the metastatic phenotype in this patient; therefore, their contribution remains conjectural. Fourth, retained ATRX expression is the expected finding in IDH-wildtype glioblastoma, as ATRX loss is strongly associated with IDH-mutant astrocytomas and is rare in IDH-wildtype tumors [63]. It does not carry independent prognostic significance in this molecular context. Although gliosarcomatous differentiation has been associated with an increased propensity for extracranial spread, the absence of dedifferentiated or sarcomatous features demonstrates that early systemic dissemination may also occur in conventional IDH-wildtype GBM [64]. Taken together, the molecular profile of this tumor is consistent with an aggressive proliferative phenotype that may have facilitated early extracranial dissemination. The co-occurrence of TP53 alteration and SOX10 disruption is particularly noteworthy, as both have been independently linked to invasive and metastatic behavior in GBM. However, these associations cannot establish causality from a single case and should be considered hypothesis-generating. Likewise, it is plausible that MGMT methylation-mediated sensitivity to TMZ contributed to prolonged survival, as MGMT promoter methylation is an established predictive biomarker for benefit from TMZ-containing therapy in IDH-wildtype GBM [65]. However, this inference cannot be established from a single case. Notably, Zhang et al. reported that MGMT promoter methylation was actually less common in GBM cases with extraneural metastasis (31.8%, 7/22) compared to unselected TCGA GBM (48.6%, 170/350), although this difference was not statistically significant [50]. Therefore, any causal relationship between MGMT status and metastatic behavior cannot be inferred from a single case. Rather, this observation should be viewed as hypothesis-generating and warrants further investigation in larger cohorts. Treatment strategies in metastatic GBM vary widely and are largely palliative. In our case, both intracranial and pulmonary lesions were treated with radiation therapy followed by systemic TMZ. While TMZ is the current standard of care for newly diagnosed GBM, its role in controlling established extracranial metastatic disease remains uncertain. Some case reports have incorporated agents such as bevacizumab, irinotecan, or etoposide, but responses have been variable and no consensus systemic regimen currently exists for metastatic GBM [6,26]. The possibility of incorporating immunotherapy was reviewed through multidisciplinary discussion involving neuro-oncology specialists at two tertiary-care institutions; however, given the available evidence and the patient's clinical status, consensus was that immunotherapy was unlikely to provide meaningful clinical benefit. This case therefore highlights the importance of individualized multidisciplinary decision-making in the absence of evidence-based treatment guidelines. The present case also raises important questions regarding the timing of extracranial dissemination. Although this patient's pulmonary lesion was identified during her initial diagnostic evaluation, it remains uncertain whether metastatic spread occurred before clinical presentation or developed rapidly during the perioperative period. Consequently, this report cannot establish the precise timing or mechanism of systemic dissemination. Nevertheless, it demonstrates that clinically significant extracranial disease may already be present at or shortly after diagnosis in rare patients. Accordingly, our findings should not be interpreted as supporting routine systemic screening for all patients with GBM. Rather, this case generates the hypothesis that selective extracranial imaging (i.e., contrast enhance CT of the chest, abdomen, and pelvis, or PET/CT) may warrant future investigation in carefully selected patients with atypical systemic symptoms, suspicious extracranial imaging findings, or unusual clinical trajectories. The optimal timing, modality, and target population for such screening remain undefined. Prospective studies will be required to determine whether risk-stratified surveillance strategies can improve diagnosis, management, or patient outcomes. Conclusion In conclusion, this case highlights three important observations regarding extracranial metastatic GBM: (1) biopsy-confirmed extracranial dissemination may occur much earlier than is generally appreciated, (2) prolonged survival following pulmonary metastases, although uncommon, is possible and likely reflects substantial biologic heterogeneity among metastatic GBM, and (3) current evidence is insufficient to support routine extracranial screening or standardized treatment strategies, underscoring the need for prospective investigation. The molecular profile of this tumor, IDH-wildtype, MGMT-methylated, p53-immunopositive in approximately 60% of tumor cells, Ki-67 labeling index of 40%, retained ATRX expression, and SOX10 mutation in the metastatic lesion, provides a detailed molecular characterization that may inform future investigations into the biology of extracranial GBM dissemination. The co-occurrence of TP53 alteration and SOX10 disruption, both of which have been independently linked to invasive and metastatic behavior in GBM, is particularly noteworthy and warrants further study. Because this report describes a single patient, its findings should be considered hypothesis-generating rather than practice-changing. Future multicenter studies integrating clinical, molecular, and radiographic data will be essential to better define the mechanisms of extracranial dissemination, identify prognostic biomarkers associated with prolonged survival, and optimize management strategies for this rare but increasingly recognized manifestation of GBM. Supplementary Material CARE checklist_GBM to Lungs.pdf GBM to lungs Table 2_Supplementary Material.docx Acknowledgements OpenAI ChatGPT (GPT-5.5) was used to assist in generating the initial layout of the clinical timeline figure from an author-developed prompt. The authors reviewed, verified, and edited the figure to ensure that it accurately reflected the patient's clinical course. The authors assume full responsibility for the content and accuracy of the final figure. Funding Statement This paper was not funded Ethical declaration Written informed consent for publication of this case report and any accompanying images was obtained from the patient. The consent form is held by the authors and is available for review by the Editor of CNS Oncology upon reasonable request. A copy of the consent form has not been submitted with this manuscript in accordance with the journal’s editorial policies but can be provided at any stage, including after publication, if required. We have adhered to the CARE checklist guidelines. Authors’ contributions Colin Burns: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing (original draft, review, and editing. Cheng Chia Wu: Supervision, Validation, Writing (review & editing). Kei Suzuki: Supervision, Validation, Writing (review & editing). Grace Lee: Validation, Writing (review & editing). Daniel Kim: Conceptualization, Validation, Writing (review & editing). Disclosure statement The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. Reviewer disclosures Peer reviewers on this manuscript have received an honorarium from CNS Oncology for their review work but have no other relevant financial relationships to disclose. References Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers. Annotation: Foundational natural-history study establishing the median post-metastatic survival and the poorer prognosis of pulmonary involvement against which this case is benchmarked. Annotation: Demonstrates that extracranial metastases arise from the primary tumor and undergo molecular and transcriptional plasticity, supporting the mechanistic framework of this report. Annotation: Provides the comparative data on TP53 mutation enrichment and MGMT methylation frequency in extraneural metastatic GBM central to this Discussion. Associated Data Supplementary Materials CARE checklist_GBM to Lungs.pdf GBM to lungs Table 2_Supplementary Material.docx